Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.
In 2017, about half of physician directors at National Cancer Institute cancer centers received payments related to research, while a quarter received payments over $5,000 that were not related to research.
The combination of talimogene laherparepvec and pembrolizumab was associated with antitumor activity across a range of sarcoma histologic subtypes in this phase II clinical trial.
The company’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor.
This technology identified a practical method for detecting multiple gastrointestinal cancers from a single noninvasive blood test.
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care.
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.